This CPB has been revised to: (i) add intramuscular ketamine as expermental and investigational for the indications listed in the policy section; and (ii) state that ketamine (intramuscular, intranasal, intravenous, oral, or subcutaneous) is considered experimental and investigational for the treatment of post-traumatic stress disorder.